Now that FDA has finalized its rulemaking on lab developed tests, those involved in using diagnostics to inform clinical care decisions should take a moment to get smart on what it will take for applicable tests to fall into compliance over the next 4 years, and which types of tests will remain subject to only partial requirements. This shift creates both headwinds and tailwinds for test developers, drug manufacturers, providers, and patients. https://lnkd.in/eQ2adjif Caroline Williams Nancy El Hoyek Laura T. Housman, MPH, MBA, DrPH(c) Brigit Kyei-Baffour, MBA #Precisionmedicine #LDTs #MedicalDevices #Diagnostics
The FDA’s decision to regulate LDTs as medical devices brings numerous uncertainties to the field, but #AvalereExperts are here to help stakeholders parse through what the new rule means for them. Read our latest analysis on phaseout requirements, recent clarifications on implementation, and next steps for manufacturers of in-vitro diagnostics marketed as LDTs: https://lnkd.in/eQ2adjif Interested in learning more about the changing landscape of lab developed tests? Connect with one of our seasoned experts in regulatory strategy, evidence, and market access today: https://lnkd.in/eihYvhDm Caroline Williams, Mark Von Eisenburg, MS, Nancy El Hoyek, Laura T. Housman, MPH, MBA, DrPH(c), Brigit Kyei-Baffour, MBA #LDT #LDTs #labdevelopedtests #diagnostics #marketaccess